Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Mucopolysaccharidosis Types I, II, and VI
NCT03153319Phase 2Active, not recruiting
- Sponsor
- The Lundquist Institute
- Start
- Jun 2017
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adalimumab in mucopolysaccharidosis type I, mucopolysaccharidosis type 2 and mucopolysaccharidosis type VI (3 arms), sponsored by The Lundquist Institute. Primary endpoints: Pain at 16 weeks and Adalimumab trough concentration at 32 weeks. Started Jun 2017; status: active, not recruiting.
02
Drugs
03
Conditions
mucopolysaccharidosis type Imucopolysaccharidosis type 2mucopolysaccharidosis type VI
Beyond the preview
Go deeper on NCT03153319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153319.